Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 4 Hydroxybutyrate Sodium
2. 4-hydroxybutyrate Sodium
3. Gamma Hydroxybutyrate
4. Gamma-hydroxybutyrate
5. Oxybate Sodium
6. Oxybate, Sodium
7. Oxybutyrate, Sodium
8. Sodium Gamma Hydroxybutyrate
9. Sodium Gamma-hydroxybutyrate
10. Sodium Oxybutyrate
11. Somsanit
12. Xyrem
1. 502-85-2
2. Sodium 4-hydroxybutyrate
3. Anetamin
4. 4-hydroxybutyric Acid Sodium Salt
5. Sodium 4-hydroxybutanoate
6. Somsanit
7. Oxybate Sodium
8. Gamma Oh
9. Sodium Oxybate [usan]
10. Sodium Oxybutyrate
11. Catabate
12. Sodium Oxybat
13. Oxybate (sodium)
14. 4-hydroxybutyrate Sodium
15. Wy-3478
16. Butanoic Acid, 4-hydroxy-, Monosodium Salt
17. Gamma-hydroxybutyrate Sodium
18. Sodium Gamma-hydroxybutyrate
19. Sodium;4-hydroxybutanoate
20. Gamma-hydroxy Sodium Butyrate
21. Butanoic Acid, 4-hydroxy-, Sodium Salt
22. Eb 27
23. Hydroxybutyric Acid Monosodium Salt
24. 4-hydroxybutyric Acid Monosodium Salt
25. Wy 3478
26. .gamma.-hydroxybutyrate Sodium Salt
27. Nsc-84223
28. Sodium Oxybate (usan)
29. 7g33012534
30. Butyric Acid, 4-hydroxy-, Monosodium Salt
31. Butyric Acid, 4-hydroxy-, Sodium Salt
32. Natrium 4-hydroxybutyrat
33. Sodium-4-hydroxybutyrate
34. Sodium Oxybate (sodium 4-hydroxybutanoate)
35. Ghb Sodium Salt (sodium Gammahydroxybutyrate)
36. 4-hydroxybuttersaeure Natriumsalz
37. Gamma-hydroxybutyrate Sodium Salt
38. Ncgc00247714-01
39. Einecs 207-953-3
40. Nsc 84223
41. Gamma-hydroxybutyric Acid, Sodium Salt
42. Jzp-6
43. Sodium4-hydroxybutyrate
44. Acetamide,2,2-dichloro-n-[(1r,2r)-2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl]-,rel-
45. Unii-7g33012534
46. Xyrem (tn)
47. Sodium Gammahydroxybutyrate
48. Dsstox_cid_28866
49. Dsstox_rid_83135
50. Dsstox_gsid_48940
51. Schembl61823
52. Sodium Oxybate [hsdb]
53. Sodium Oxybate [vandf]
54. Dea No. 2012
55. Sodium Oxybate [mart.]
56. Chembl1200682
57. Dtxsid3048940
58. Oxybate Sodium [who-dd]
59. Sodium Oxybate [ema Epar]
60. Hms2091e15
61. Hy-b1187
62. Tox21_112871
63. Sodium Oxybate [orange Book]
64. Gamma Hydroxybutyric Acid Preparations
65. Xywav Component Sodium Oxybate
66. Akos006221428
67. Ccg-212465
68. Cs-4796
69. Db09072
70. Sodium Oxybate Component Of Xywav
71. Cas-502-85-2
72. Db-071156
73. Ft-0626615
74. D05866
75. H-4040
76. Sodium Salt Of Gamma-hydroxybutyric Acid
77. .gamma.-hydroxybutyrate Sodium Salt [mi]
78. Butanoic Acid, 4-hydroxy-, Sodium Salt (1:1)
79. Q7553347
80. 90318-49-3
Molecular Weight | 126.09 g/mol |
---|---|
Molecular Formula | C4H7NaO3 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 3 |
Rotatable Bond Count | 3 |
Exact Mass | 126.02928836 g/mol |
Monoisotopic Mass | 126.02928836 g/mol |
Topological Polar Surface Area | 60.4 Ų |
Heavy Atom Count | 8 |
Formal Charge | 0 |
Complexity | 64.3 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Xyrem |
PubMed Health | Sodium Oxybate (By mouth) |
Drug Classes | Central Nervous System Agent |
Drug Label | Sodium oxybate, a CNS depressant, is the active ingredient in Xyrem. The chemical name for sodium oxybate is sodium 4-hydroxybutyrate. The molecular formula is C4H7NaO3, and the molecular weight is 126.09 g/mole. The chemical structure is:Sodium oxyb... |
Active Ingredient | Sodium oxybate |
Dosage Form | Solution |
Route | Oral |
Strength | 500mg/ml |
Market Status | Prescription |
Company | Jazz Pharms |
2 of 2 | |
---|---|
Drug Name | Xyrem |
PubMed Health | Sodium Oxybate (By mouth) |
Drug Classes | Central Nervous System Agent |
Drug Label | Sodium oxybate, a CNS depressant, is the active ingredient in Xyrem. The chemical name for sodium oxybate is sodium 4-hydroxybutyrate. The molecular formula is C4H7NaO3, and the molecular weight is 126.09 g/mole. The chemical structure is:Sodium oxyb... |
Active Ingredient | Sodium oxybate |
Dosage Form | Solution |
Route | Oral |
Strength | 500mg/ml |
Market Status | Prescription |
Company | Jazz Pharms |
For the treatment of cataplexy and excessive daytime sleepiness (EDS) associated with narcolepsy.
FDA Label
Treatment of narcolepsy with cataplexy in adult patients.
Substitution treatment for alcohol dependence within a framework of careful medical supervision along with continuous psychosocial support and social rehabilitation. Treatment should be initiated only in patients resistant to existing interventions or in patients for whom existing therapies are contra-indicated or not recommended. ,
Sodium oxybate works through an unknown mechanism to treat narcolepsy by inducing sleep within about 5-15 minutes of administration.
Adjuvants, Anesthesia
Agents that are administered in association with anesthetics to increase effectiveness, improve delivery, or decrease required dosage. (See all compounds classified as Adjuvants, Anesthesia.)
Anesthetics, Intravenous
Ultrashort-acting anesthetics that are used for induction. Loss of consciousness is rapid and induction is pleasant, but there is no muscle relaxation and reflexes frequently are not reduced adequately. Repeated administration results in accumulation and prolongs the recovery time. Since these agents have little if any analgesic activity, they are seldom used alone except in brief minor procedures. (From AMA Drug Evaluations Annual, 1994, p174) (See all compounds classified as Anesthetics, Intravenous.)
N07XX04
N07BB
B05XA02
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
N - Nervous system
N01 - Anesthetics
N01A - Anesthetics, general
N01AX - Other general anesthetics
N01AX11 - Sodium oxybate
N - Nervous system
N07 - Other nervous system drugs
N07X - Other nervous system drugs
N07XX - Other nervous system drugs
N07XX04 - Sodium oxybate
Absorption
Absolute bioavailability is approximately 88%. Tmax of 30.7-51.9min.
Route of Elimination
The major metabolite is carbon dioxide which is cleared by expiration, less then 5% appears as the unchanged drug in the urine within 6-8 hours after dosing.
Volume of Distribution
Vd of 37.7-67.7
Clearance
Total clearance of 895-1361mL/min.
Animal studies indicate that the major elimination pathway is metabolism by the creation of carbon dioxide and water through the Krebs cycle and secondarily by beta-oxidation. In the primary pathway hydroxyacid-oxoacid transhydrogenase catalyzes the conversion of sodium oxybate to succinic semialdehyde which is then transformed to succinic acid by succinic semmialdehyde dehydrogenase. Succinic acid is then turned into carbon dioxide and water in the Krebs cycle. Succinic semialdehyde is also metabolised into carbon dioxide and water by a transhydrofenase in the presence of alpha ketoglutarate.
0.5 to 1 hour.
The exact mechanism of action is unknown. It is the sodium salt of the endogenous compound gamma hydroxybutyrate which is a metabolite of the GABA neurotransmitter and it's thought that it's therapeutic effects are mediated via GABA B actions at noradrenergic, dopaminergic and thalamocortical neurons.
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
65
PharmaCompass offers a list of Gamma-Hydroxybutyric Acid Sodium API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Gamma-Hydroxybutyric Acid Sodium manufacturer or Gamma-Hydroxybutyric Acid Sodium supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Gamma-Hydroxybutyric Acid Sodium manufacturer or Gamma-Hydroxybutyric Acid Sodium supplier.
PharmaCompass also assists you with knowing the Gamma-Hydroxybutyric Acid Sodium API Price utilized in the formulation of products. Gamma-Hydroxybutyric Acid Sodium API Price is not always fixed or binding as the Gamma-Hydroxybutyric Acid Sodium Price is obtained through a variety of data sources. The Gamma-Hydroxybutyric Acid Sodium Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A gamma-Hydroxybutyric acid sodium salt manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of gamma-Hydroxybutyric acid sodium salt, including repackagers and relabelers. The FDA regulates gamma-Hydroxybutyric acid sodium salt manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. gamma-Hydroxybutyric acid sodium salt API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of gamma-Hydroxybutyric acid sodium salt manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A gamma-Hydroxybutyric acid sodium salt supplier is an individual or a company that provides gamma-Hydroxybutyric acid sodium salt active pharmaceutical ingredient (API) or gamma-Hydroxybutyric acid sodium salt finished formulations upon request. The gamma-Hydroxybutyric acid sodium salt suppliers may include gamma-Hydroxybutyric acid sodium salt API manufacturers, exporters, distributors and traders.
click here to find a list of gamma-Hydroxybutyric acid sodium salt suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A gamma-Hydroxybutyric acid sodium salt DMF (Drug Master File) is a document detailing the whole manufacturing process of gamma-Hydroxybutyric acid sodium salt active pharmaceutical ingredient (API) in detail. Different forms of gamma-Hydroxybutyric acid sodium salt DMFs exist exist since differing nations have different regulations, such as gamma-Hydroxybutyric acid sodium salt USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A gamma-Hydroxybutyric acid sodium salt DMF submitted to regulatory agencies in the US is known as a USDMF. gamma-Hydroxybutyric acid sodium salt USDMF includes data on gamma-Hydroxybutyric acid sodium salt's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The gamma-Hydroxybutyric acid sodium salt USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of gamma-Hydroxybutyric acid sodium salt suppliers with USDMF on PharmaCompass.
A gamma-Hydroxybutyric acid sodium salt written confirmation (gamma-Hydroxybutyric acid sodium salt WC) is an official document issued by a regulatory agency to a gamma-Hydroxybutyric acid sodium salt manufacturer, verifying that the manufacturing facility of a gamma-Hydroxybutyric acid sodium salt active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting gamma-Hydroxybutyric acid sodium salt APIs or gamma-Hydroxybutyric acid sodium salt finished pharmaceutical products to another nation, regulatory agencies frequently require a gamma-Hydroxybutyric acid sodium salt WC (written confirmation) as part of the regulatory process.
click here to find a list of gamma-Hydroxybutyric acid sodium salt suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing gamma-Hydroxybutyric acid sodium salt as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for gamma-Hydroxybutyric acid sodium salt API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture gamma-Hydroxybutyric acid sodium salt as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain gamma-Hydroxybutyric acid sodium salt and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a gamma-Hydroxybutyric acid sodium salt NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of gamma-Hydroxybutyric acid sodium salt suppliers with NDC on PharmaCompass.
gamma-Hydroxybutyric acid sodium salt Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of gamma-Hydroxybutyric acid sodium salt GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right gamma-Hydroxybutyric acid sodium salt GMP manufacturer or gamma-Hydroxybutyric acid sodium salt GMP API supplier for your needs.
A gamma-Hydroxybutyric acid sodium salt CoA (Certificate of Analysis) is a formal document that attests to gamma-Hydroxybutyric acid sodium salt's compliance with gamma-Hydroxybutyric acid sodium salt specifications and serves as a tool for batch-level quality control.
gamma-Hydroxybutyric acid sodium salt CoA mostly includes findings from lab analyses of a specific batch. For each gamma-Hydroxybutyric acid sodium salt CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
gamma-Hydroxybutyric acid sodium salt may be tested according to a variety of international standards, such as European Pharmacopoeia (gamma-Hydroxybutyric acid sodium salt EP), gamma-Hydroxybutyric acid sodium salt JP (Japanese Pharmacopeia) and the US Pharmacopoeia (gamma-Hydroxybutyric acid sodium salt USP).